Beyond Piperacillin-Tazobactam: Cefepime and AAI101 as a Potent β-Lactam−β-Lactamase Inhibitor Combination

Impeding, as well as reducing, the burden of antimicrobial resistance in Gram-negative pathogens is an urgent public health endeavor. Our current antibiotic armamentarium is dwindling, while major resistance determinants (e.g., extended-spectrum β-lactamases [ESBLs]) continue to evolve and dissemina...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Antimicrob Agents Chemother
Autors principals: Papp-Wallace, Krisztina M., Bethel, Christopher R., Caillon, Jocelyne, Barnes, Melissa D., Potel, Gilles, Bajaksouzian, Saralee, Rutter, Joseph D., Reghal, Amokrane, Shapiro, Stuart, Taracila, Magdalena A., Jacobs, Michael R., Bonomo, Robert A., Jacqueline, Cédric
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2019
Matèries:
Experimental Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6496078/
https://ncbi.nlm.nih.gov/pubmed/30858223
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00105-19
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars